Trial Profile
An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 6047 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech
- 30 Jan 2020 Status changed from active, no longer recruiting to completed.
- 19 Dec 2019 Planned End Date changed from 30 Nov 2019 to 2 Jan 2020.
- 19 Dec 2019 Planned primary completion date changed from 30 Nov 2019 to 2 Jan 2020.